Multiple Myeloma (MM) still remains an incurable disease. This is predominantly due to development of drug resistance in tumor cells which eventually leads to relapse of the disease. JS-K is a novel agent that is designed to turn one of the major resistance mechanisms developed by tumor cells to their disadvantage to kill them. The preliminary results presented in this proposal show that JS-K selectively induces death even in MM cells resistant to standard treatments. Here I propose to evaluate the efficacy of JS-K in animal models and take it forward clinically alone and in combination with other conventional and/or novel drugs, to improve treatment of MM.